D. Oh

Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response

Background Most cholangiocarcinoma (CCA) patients are diagnosed with advanced disease and are ineligible for surgery. First-line, standard-of-care therapy for patients with advanced/metas...

G. Vaccaro ;

D. Melisi ;

R. Al-Rajabi ;

A. Paulson ;

M. Borad ;

D. Gallinson ;

D. Oh ;

E. Dotan ;

Daniel Catenacci , MD;

Eric Van Cutsem , MD, PhD;

A. Murphy ;

C. Lihou ;

H. Ren ;

K. Bibeau ;

Ghassan Abou-Alfa , MD, MBA;

L. Feliz ;

V. Sahai ;

Arndt Vogel , MD;

A. Hollebecque ;

06/28/2021

PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

Background First-line treatment options are limited for patients with advanced cholangiocarcinoma (CCA). Genetic alterations in the fibroblast growth factor receptor (FG...

Teresa Macarulla , MD, PhD;

Sudipta Roychowdhury , MD;

R. Shroff ;

J. Soto ;

G. Pedrioli ;

L. Fumagalli ;

C. dambkowski ;

M. Javle ;

Ghassan Abou-Alfa , MD, MBA;

D. Oh ;

I. Borbath ;

Lovely Goyal ;

Angela Lamarca , MD, PhD, MSc;

06/27/2022

Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset

Background Neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions are oncogenic drivers in various tumour types. Larotrectinib is a first-in-class, highly selective tropomyosin rece...

Jordan D. Berlin ;

C. Mussi ;

D. Oh ;

Serge Leyvraz ;

A. Drilon ;

Maria de Miguel ;

Yongmei Liu ;

Marc Fellous ;

Lin Shen ;

Thierry André , MD;

Elena Garralda ;

Aitana Ferrandiz ;